



Joint Action
Antimicrobial Resistance and
Healthcare-Associated Infections

Keynote

2nd EU-JAMRAI General Assembly

Opening Keynote

Professor Marie-Cécile Ploy
EU-JAMRAI Coordinator, INSERM, France

16th September 2019
Rome, Italy

Dear distinguished guests,
Dear partners of the Joint action,
Dear representatives of international organisations and stakeholders,
Ladies and gentlemen,

It is my pleasure to welcome you here for the Second General Assembly of the European Joint Action on AMR and Healthcare Associated infection, EU-JAMRAI.

Within the EU-JAMRAI, we have the pleasure to assemble 44 partners from 27 countries, and more than 40 stakeholders.

I would like to thank all of you for attending this meeting and in particular the Istituto Superiore di Sanita, for hosting us today. Your presence today is the witness of your continued commitment to tackling Antimicrobial resistance and healthcare associated infections.

Looking back - the vision is still relevant



Prof. Marie-Cécile Ploy during EU-JAMRAI 2nd GA opening

The Kick-off meeting of the EU-JAMRAI was in September 2017, only 2 years ago. I would like to thank all the partners involved in this JA. You all have worked very hard. Today, I'm happy we can show you the main concrete actions, and discuss with all of you how to go further to have a sustainable impact on AMR and HCAI.

Last year in Vienna many of you were already there. We expressed our vision: fostering synergies among a wide variety of actors from civil society, healthcare professionals, industrials, international organisations to policymakers, in both animal and human sectors. We also presented preliminary results and shared these with you all. We



Co-funded by the
Health Programme
of the European Union

EU-JAMRAI Communication Office | aemps.jamrai@aemps.es | (+34) 918225523/25/26



Joint Action
Antimicrobial Resistance and
Healthcare-Associated Infections

collected feedback and contributions that enabled us to further work on proposing evidence-based actions.

The European and international context about AMR has changed. New studies and reports urge decision-makers to act. AMR is still high on the political agenda at national, European and International level. Although this Joint Action is only a 3 year project, it is a unique place where all key players can discuss and propose solutions.

The forthcoming European Commission that Ursula Van der Leyen is constituting has identified AMR as a high priority. This gives us encouraging signs that European cooperation in this field will continue.

Yes, AMR reduction is a considerable challenge, but feasible if all actors take concrete actions. We are accountable to the younger generations of the measures we take now. So, we cannot afford to work in silos. We cannot afford to stop our efforts. We have all to continue our collective effort at national, European and international level

A brief overview of the two days of meetings

Today, we will start the day with a keynote address by Mr Silvio Brusafero, director of the Istituto superior di Sanita. Thank you so much for being with us today.

After this keynote, the rest of the day will be dedicated to the presentation of the results of the Joint Action.

Then, Prof. Pulcini, the MoH Coordinator of the French AMR National Action Plan, will conclude this day.

Tomorrow, we will be launching our 2nd Stakeholder Forum that gives the opportunity to the stakeholders to share their experience and provide us with recommendations.

This SF will start with a keynote address from Mr. Charles Price from DG Santé followed by three roundtables. These roundtables will focus on Incentives for Stimulating Innovation & Access to Antimicrobials, Challenges to antimicrobial stewardship in animal health, Sustainability plan for the EU-JAMRAI outputs. The moderators of these round tables are Michele Cecchini from OECD, Ernesto Liebana from EFSA and again Charles Price from DG Santé.

Today's workplan

Today, we will organize the presentation of our results in 3 sessions. The first one will focus on How to strengthen national response to tackle AMR. The second one will debate on Infection prevention and control and ask How could we fill the gaps between implementation, research and communication. The third one will be dedicated to Antibiotic stewardship and surveillance with a concrete record about how influencing policy with evidence.

I would like specially to thank the JA team for fostering the synergies to present you today our experience and highlight the barriers and opportunities to tackle AMR.





Joint Action
Antimicrobial Resistance and
Healthcare-Associated Infections

I have also to thank warmly the European and international organisations that EU-JAMRAI partners have liaised with, and all countries involved in the EU-JAMRAI. Your continued commitment is the key to success!

Finally, I would like to thank warmly Annalisa Pantosti from ISS, and also Sadika, Laura, Angela, and Hannah for the perfect organization of these 3 days.

Concluding remarks

Let me end up my speech by saying that The European Joint Action on Antimicrobial Resistance and Healthcare-Associated Infections aims to give a new dimension to the AMR issue and make Europe a leader in the field, keeping in mind that AMR concerns everyone, from low to high income countries.

As I said previously, we are accountable to the younger generations for the measures and actions we take now. So, we cannot afford to leave to the next generation a world with uncontrolled antimicrobial resistance. We have to take off this burden from their shoulders.

Working hand in hand, each within the remit of our competence, we will find better solutions, for a sustainable common European strategy, against AMR.

Working hand in hand, will allow us to maximise our resources and improve our impact.

Together we will move forward, further & faster, to achieve our shared objectives!

As coordinator, I'm pleased to declare open this second General Assembly and delighted to call Mr Silvio Brusafiero.

I wish you a very productive working day.

Thank you

This document arises from the Joint Action on Antimicrobial Resistance and Healthcare- Associated Injections (EU-JAMRAI), which has received funding from the European Union, in the framework of the Health Program (2014-2020) under the Grant Agreement N°761296. Sole responsibility lies with the author and the Consumers, Health, Agriculture and Food Executive Agency is not responsible for any use that may be made of the information contained herein.

The total or partial reproduction of this content is authorized as long as the source (EU-JAMRAI) is expressly mentioned.

EU-JAMRAI Communication Office Contact: aemps.jamrai@aemps.es

